F Stephen Hodi — ASN Events

F Stephen Hodi — ASN Events

, ,

Presentations this author is a contributor to:

Clinical response, progression-free survival (PFS) and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) versus IPI monotherapy in CheckMate 069 study (#163)

Best of the Best Posters - Epidemiology & Health services

Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067) (#204)